Eric Ho is a dynamic Senior Scientist specializing in antibody discovery and development, with a strong background in computational biology. With a PhD in Medical Biophysics from the University of Toronto, Eric has extensive expertise in biological therapeutic development, including molecular biology, cell biology, and protein engineering. Currently at AstraZeneca, Eric is involved with hybridoma and B-cell technology, after previously contributing to antibody lead identification at Hengenix Biotech, Inc. Additionally, Eric has experience in next-generation sequencing projects and has a keen interest in developing innovative research techniques.
This person is not in the org chart
This person is not in any teams
This person is not in any offices